Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endothelium, Vascular | 23 | 2021 | 4455 | 1.990 |
Why?
|
Vasodilation | 18 | 2020 | 944 | 1.820 |
Why?
|
Endothelin-1 | 8 | 2015 | 313 | 1.380 |
Why?
|
Cardiology | 5 | 2022 | 1658 | 1.130 |
Why?
|
Committee Membership | 2 | 2020 | 15 | 0.920 |
Why?
|
Vascular Diseases | 3 | 2020 | 1155 | 0.870 |
Why?
|
Peripheral Arterial Disease | 5 | 2020 | 1184 | 0.870 |
Why?
|
Societies, Medical | 3 | 2020 | 3740 | 0.860 |
Why?
|
Brachial Artery | 7 | 2020 | 370 | 0.810 |
Why?
|
Forearm | 12 | 2015 | 407 | 0.730 |
Why?
|
PPAR gamma | 3 | 2014 | 493 | 0.660 |
Why?
|
Thiazolidinediones | 3 | 2014 | 476 | 0.660 |
Why?
|
Aortic Rupture | 1 | 2021 | 310 | 0.630 |
Why?
|
Arteries | 3 | 2020 | 1118 | 0.570 |
Why?
|
Hematoma | 1 | 2021 | 755 | 0.550 |
Why?
|
Venous Thromboembolism | 4 | 2023 | 1668 | 0.540 |
Why?
|
Endothelins | 2 | 2014 | 138 | 0.530 |
Why?
|
Renal Veins | 1 | 2015 | 108 | 0.510 |
Why?
|
Vasodilator Agents | 6 | 2023 | 976 | 0.500 |
Why?
|
Biomedical Research | 2 | 2020 | 3306 | 0.440 |
Why?
|
Osteoprotegerin | 2 | 2019 | 176 | 0.440 |
Why?
|
Renal Artery | 1 | 2015 | 398 | 0.440 |
Why?
|
Hypercholesterolemia | 3 | 2014 | 1149 | 0.430 |
Why?
|
Pulmonary Embolism | 5 | 2022 | 2370 | 0.420 |
Why?
|
Cardiovascular Diseases | 8 | 2022 | 15108 | 0.410 |
Why?
|
Obesity | 11 | 2023 | 12705 | 0.410 |
Why?
|
Arteriovenous Fistula | 1 | 2015 | 315 | 0.410 |
Why?
|
Hyperinsulinism | 4 | 2012 | 415 | 0.400 |
Why?
|
Acetanilides | 1 | 2012 | 168 | 0.380 |
Why?
|
Anticoagulants | 6 | 2023 | 4595 | 0.360 |
Why?
|
Mentors | 3 | 2020 | 630 | 0.350 |
Why?
|
Atrial Fibrillation | 4 | 2023 | 5019 | 0.350 |
Why?
|
Leadership | 1 | 2019 | 1357 | 0.340 |
Why?
|
Neoplasms | 6 | 2022 | 21596 | 0.340 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 2723 | 0.340 |
Why?
|
Hospital Mortality | 3 | 2021 | 5310 | 0.330 |
Why?
|
Femoral Artery | 5 | 2016 | 843 | 0.320 |
Why?
|
Peptides, Cyclic | 7 | 2015 | 401 | 0.320 |
Why?
|
Medical Oncology | 2 | 2022 | 2235 | 0.320 |
Why?
|
Nitroprusside | 7 | 2023 | 275 | 0.320 |
Why?
|
Flavonols | 1 | 2008 | 83 | 0.320 |
Why?
|
Cardiac Output | 1 | 2010 | 853 | 0.310 |
Why?
|
Vasoconstriction | 2 | 2015 | 596 | 0.300 |
Why?
|
Hypertension | 11 | 2016 | 8455 | 0.300 |
Why?
|
Cacao | 1 | 2008 | 98 | 0.300 |
Why?
|
Cardiotonic Agents | 1 | 2010 | 535 | 0.300 |
Why?
|
Insulin Resistance | 6 | 2014 | 3861 | 0.290 |
Why?
|
American Heart Association | 3 | 2022 | 1055 | 0.280 |
Why?
|
Acetylcholine | 7 | 2023 | 621 | 0.280 |
Why?
|
Diabetes Mellitus, Type 2 | 9 | 2020 | 11695 | 0.270 |
Why?
|
Takotsubo Cardiomyopathy | 2 | 2018 | 125 | 0.270 |
Why?
|
Hypertension, Pulmonary | 1 | 2015 | 1527 | 0.240 |
Why?
|
Electrocardiography | 3 | 2018 | 6440 | 0.230 |
Why?
|
History, 21st Century | 2 | 2020 | 1533 | 0.210 |
Why?
|
Infusions, Intra-Arterial | 5 | 2015 | 231 | 0.210 |
Why?
|
Career Choice | 2 | 2020 | 743 | 0.210 |
Why?
|
Stroke | 2 | 2023 | 9963 | 0.210 |
Why?
|
Hypoglycemic Agents | 5 | 2020 | 2866 | 0.200 |
Why?
|
Piperazines | 1 | 2012 | 2488 | 0.200 |
Why?
|
Acute Coronary Syndrome | 2 | 2012 | 2337 | 0.200 |
Why?
|
Heart Failure | 7 | 2015 | 10856 | 0.200 |
Why?
|
Nitric Oxide | 4 | 2014 | 2128 | 0.200 |
Why?
|
Ischemia | 3 | 2019 | 1911 | 0.200 |
Why?
|
Humans | 77 | 2023 | 742088 | 0.190 |
Why?
|
History, 20th Century | 2 | 2020 | 2739 | 0.190 |
Why?
|
Gastrointestinal Hormones | 1 | 2021 | 97 | 0.190 |
Why?
|
Chemokine CX3CL1 | 1 | 2020 | 58 | 0.180 |
Why?
|
Aortitis | 1 | 2020 | 73 | 0.180 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2002 | 371 | 0.180 |
Why?
|
Regional Blood Flow | 7 | 2015 | 1525 | 0.180 |
Why?
|
Risk Factors | 15 | 2023 | 72145 | 0.180 |
Why?
|
Embolism | 1 | 2023 | 409 | 0.180 |
Why?
|
Insulin | 5 | 2014 | 6575 | 0.180 |
Why?
|
Atherosclerosis | 3 | 2023 | 3428 | 0.170 |
Why?
|
Fatty Acids, Omega-3 | 3 | 2015 | 1341 | 0.170 |
Why?
|
Aortography | 1 | 2020 | 431 | 0.170 |
Why?
|
Acute Disease | 3 | 2022 | 7141 | 0.160 |
Why?
|
District of Columbia | 2 | 2016 | 157 | 0.150 |
Why?
|
Thrombolytic Therapy | 4 | 2022 | 2161 | 0.150 |
Why?
|
Cross-Over Studies | 4 | 2014 | 2030 | 0.150 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 13655 | 0.150 |
Why?
|
Carotid Artery Diseases | 1 | 2023 | 882 | 0.140 |
Why?
|
Popliteal Artery | 2 | 2016 | 317 | 0.140 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2018 | 339 | 0.140 |
Why?
|
Giant Cell Arteritis | 1 | 2020 | 292 | 0.140 |
Why?
|
Intermittent Claudication | 1 | 2019 | 309 | 0.140 |
Why?
|
Carotid Stenosis | 1 | 2023 | 854 | 0.140 |
Why?
|
Thrombosis | 2 | 2023 | 2966 | 0.140 |
Why?
|
Cholesterol, HDL | 2 | 2018 | 1813 | 0.140 |
Why?
|
Heparin | 1 | 2023 | 1636 | 0.130 |
Why?
|
Aortic Aneurysm | 1 | 2020 | 643 | 0.130 |
Why?
|
Ischemic Attack, Transient | 1 | 2021 | 934 | 0.130 |
Why?
|
Adipose Tissue | 4 | 2021 | 3278 | 0.130 |
Why?
|
Administration, Oral | 3 | 2020 | 3913 | 0.130 |
Why?
|
Tissue Plasminogen Activator | 1 | 2021 | 1262 | 0.130 |
Why?
|
Aortic Diseases | 1 | 2021 | 741 | 0.130 |
Why?
|
Thromboembolism | 1 | 2020 | 983 | 0.120 |
Why?
|
Risk Assessment | 4 | 2020 | 23320 | 0.120 |
Why?
|
Nanomedicine | 1 | 2017 | 304 | 0.120 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2023 | 1181 | 0.120 |
Why?
|
Double-Blind Method | 7 | 2020 | 12017 | 0.120 |
Why?
|
Incretins | 1 | 2014 | 88 | 0.120 |
Why?
|
Female | 39 | 2023 | 379592 | 0.110 |
Why?
|
Middle Aged | 31 | 2021 | 213127 | 0.110 |
Why?
|
Cholesterol, LDL | 2 | 2018 | 2354 | 0.110 |
Why?
|
Benzazepines | 2 | 2015 | 326 | 0.110 |
Why?
|
Glutathione Transferase | 1 | 2015 | 595 | 0.110 |
Why?
|
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2012 | 57 | 0.110 |
Why?
|
Peripheral Vascular Diseases | 1 | 2016 | 550 | 0.110 |
Why?
|
Male | 37 | 2023 | 349538 | 0.110 |
Why?
|
Graft Occlusion, Vascular | 1 | 2016 | 548 | 0.110 |
Why?
|
Blood Coagulation | 1 | 2018 | 1126 | 0.110 |
Why?
|
Catheterization, Peripheral | 1 | 2016 | 344 | 0.110 |
Why?
|
Ghrelin | 1 | 2014 | 266 | 0.110 |
Why?
|
Fatty Acids, Nonesterified | 1 | 2014 | 402 | 0.110 |
Why?
|
Endovascular Procedures | 2 | 2016 | 1973 | 0.100 |
Why?
|
Guideline Adherence | 1 | 2022 | 2266 | 0.100 |
Why?
|
Guanylate Cyclase | 1 | 2013 | 201 | 0.100 |
Why?
|
Recurrence | 3 | 2021 | 8333 | 0.100 |
Why?
|
Exercise Therapy | 1 | 2019 | 904 | 0.100 |
Why?
|
Cyclic GMP | 1 | 2013 | 408 | 0.100 |
Why?
|
Angioplasty, Balloon | 1 | 2016 | 653 | 0.100 |
Why?
|
Treatment Outcome | 14 | 2020 | 62966 | 0.100 |
Why?
|
Triglycerides | 2 | 2014 | 2450 | 0.100 |
Why?
|
Blood Pressure | 9 | 2013 | 8541 | 0.100 |
Why?
|
Etiocholanolone | 1 | 2010 | 7 | 0.100 |
Why?
|
Fabry Disease | 2 | 2002 | 90 | 0.100 |
Why?
|
Lower Extremity | 1 | 2019 | 1151 | 0.100 |
Why?
|
Hospitalization | 3 | 2018 | 10232 | 0.100 |
Why?
|
Blood Vessel Prosthesis | 1 | 2016 | 933 | 0.100 |
Why?
|
rho-Associated Kinases | 1 | 2012 | 279 | 0.090 |
Why?
|
Toll-Like Receptor 4 | 1 | 2014 | 561 | 0.090 |
Why?
|
Fibrinolytic Agents | 2 | 2021 | 2156 | 0.090 |
Why?
|
Hemorrhage | 2 | 2022 | 3461 | 0.090 |
Why?
|
Calcinosis | 1 | 2019 | 1497 | 0.090 |
Why?
|
Potassium | 1 | 2015 | 1336 | 0.090 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2012 | 334 | 0.090 |
Why?
|
Dobutamine | 1 | 2010 | 123 | 0.090 |
Why?
|
Aged | 17 | 2023 | 162944 | 0.090 |
Why?
|
Hydrazones | 1 | 2010 | 102 | 0.090 |
Why?
|
Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2010 | 127 | 0.090 |
Why?
|
Lipoproteins, HDL | 1 | 2014 | 637 | 0.090 |
Why?
|
Ryanodine Receptor Calcium Release Channel | 1 | 2010 | 176 | 0.090 |
Why?
|
Digoxin | 1 | 2010 | 250 | 0.090 |
Why?
|
Creatinine | 1 | 2015 | 1916 | 0.080 |
Why?
|
Stroke Volume | 4 | 2016 | 4983 | 0.080 |
Why?
|
Drug-Eluting Stents | 1 | 2016 | 753 | 0.080 |
Why?
|
Prevalence | 3 | 2021 | 15194 | 0.080 |
Why?
|
Stents | 2 | 2023 | 3276 | 0.080 |
Why?
|
Th1 Cells | 1 | 2014 | 1056 | 0.080 |
Why?
|
Pyridazines | 1 | 2010 | 201 | 0.080 |
Why?
|
Urea | 1 | 2010 | 449 | 0.080 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 867 | 0.080 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 2010 | 494 | 0.080 |
Why?
|
Diabetic Nephropathies | 1 | 2015 | 983 | 0.080 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2011 | 361 | 0.080 |
Why?
|
Diabetes Complications | 1 | 2015 | 1359 | 0.080 |
Why?
|
C-Reactive Protein | 3 | 2016 | 3766 | 0.080 |
Why?
|
Exercise Test | 4 | 2019 | 2075 | 0.070 |
Why?
|
Hemodynamics | 2 | 2013 | 4197 | 0.070 |
Why?
|
Hypotension | 1 | 2013 | 880 | 0.070 |
Why?
|
Plethysmography | 2 | 2004 | 180 | 0.070 |
Why?
|
Interleukin-16 | 1 | 2005 | 33 | 0.070 |
Why?
|
Energy Metabolism | 2 | 2021 | 2896 | 0.070 |
Why?
|
Arteriolosclerosis | 1 | 2005 | 19 | 0.070 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2016 | 1384 | 0.070 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2007 | 153 | 0.070 |
Why?
|
Adipokines | 1 | 2008 | 318 | 0.070 |
Why?
|
Animals | 8 | 2021 | 168561 | 0.070 |
Why?
|
NF-kappa B | 1 | 2014 | 2500 | 0.070 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2007 | 707 | 0.060 |
Why?
|
Education, Medical | 1 | 2017 | 1717 | 0.060 |
Why?
|
Ticlopidine | 1 | 2011 | 899 | 0.060 |
Why?
|
Time Factors | 5 | 2020 | 40054 | 0.060 |
Why?
|
Registries | 1 | 2020 | 8077 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2016 | 2145 | 0.060 |
Why?
|
Collateral Circulation | 1 | 2005 | 287 | 0.060 |
Why?
|
Cause of Death | 2 | 2015 | 3571 | 0.060 |
Why?
|
Coronary Stenosis | 1 | 2011 | 834 | 0.060 |
Why?
|
Sex Characteristics | 1 | 2015 | 2585 | 0.060 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2011 | 851 | 0.060 |
Why?
|
Dementia | 1 | 2018 | 2501 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2018 | 3336 | 0.060 |
Why?
|
Intercellular Adhesion Molecule-1 | 2 | 2007 | 1155 | 0.060 |
Why?
|
Oligopeptides | 3 | 2004 | 1176 | 0.060 |
Why?
|
Heart Ventricles | 2 | 2015 | 3801 | 0.060 |
Why?
|
Cholesterol | 2 | 2003 | 2895 | 0.060 |
Why?
|
Glucose | 2 | 2012 | 4391 | 0.060 |
Why?
|
Vascular Patency | 2 | 2016 | 885 | 0.060 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2011 | 1873 | 0.060 |
Why?
|
Inpatients | 1 | 2015 | 2495 | 0.060 |
Why?
|
Carotid Arteries | 2 | 2023 | 952 | 0.060 |
Why?
|
Adult | 19 | 2023 | 213712 | 0.050 |
Why?
|
Patient Discharge | 1 | 2015 | 3300 | 0.050 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2005 | 675 | 0.050 |
Why?
|
Exercise | 1 | 2019 | 5611 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 4 | 2016 | 6534 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3130 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3236 | 0.050 |
Why?
|
Hemorheology | 1 | 2002 | 145 | 0.050 |
Why?
|
Myocardium | 2 | 2012 | 4775 | 0.050 |
Why?
|
Lipocalins | 1 | 2023 | 170 | 0.050 |
Why?
|
Ascorbic Acid | 1 | 2005 | 647 | 0.050 |
Why?
|
Nitroglycerin | 1 | 2002 | 325 | 0.050 |
Why?
|
Blood Flow Velocity | 2 | 2002 | 1423 | 0.050 |
Why?
|
Piperidines | 3 | 2004 | 1602 | 0.050 |
Why?
|
Quality of Life | 2 | 2019 | 12730 | 0.050 |
Why?
|
Satiation | 1 | 2021 | 80 | 0.050 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2015 | 2195 | 0.050 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2011 | 2059 | 0.050 |
Why?
|
Aorta | 2 | 2021 | 2057 | 0.050 |
Why?
|
Radial Artery | 1 | 2002 | 194 | 0.050 |
Why?
|
Enzyme Activation | 1 | 2006 | 3701 | 0.040 |
Why?
|
United States | 4 | 2022 | 69693 | 0.040 |
Why?
|
Glyburide | 1 | 2020 | 113 | 0.040 |
Why?
|
Blood Glucose | 2 | 2019 | 6249 | 0.040 |
Why?
|
Ephedrine | 1 | 1999 | 54 | 0.040 |
Why?
|
Dilatation, Pathologic | 1 | 2020 | 520 | 0.040 |
Why?
|
Prosthesis Design | 2 | 2016 | 2110 | 0.040 |
Why?
|
Chemokine CCL5 | 1 | 2019 | 209 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2015 | 7901 | 0.040 |
Why?
|
Echocardiography | 3 | 2018 | 5097 | 0.040 |
Why?
|
Arthritis, Rheumatoid | 1 | 2014 | 3695 | 0.040 |
Why?
|
Aged, 80 and over | 2 | 2021 | 57683 | 0.040 |
Why?
|
Adrenergic alpha-Agonists | 1 | 1999 | 177 | 0.040 |
Why?
|
Catheters | 1 | 2021 | 422 | 0.040 |
Why?
|
Case-Control Studies | 5 | 2020 | 21719 | 0.040 |
Why?
|
Ventricular Function, Left | 1 | 2011 | 3656 | 0.040 |
Why?
|
Osteopontin | 1 | 2019 | 296 | 0.040 |
Why?
|
Prognosis | 4 | 2020 | 29010 | 0.040 |
Why?
|
Coronary Artery Disease | 1 | 2017 | 6454 | 0.040 |
Why?
|
Medication Errors | 1 | 2023 | 797 | 0.040 |
Why?
|
Pyridones | 1 | 2021 | 712 | 0.040 |
Why?
|
Patients | 1 | 2023 | 892 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 5522 | 0.030 |
Why?
|
Vasoconstrictor Agents | 1 | 1999 | 643 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2014 | 5724 | 0.030 |
Why?
|
Retrospective Studies | 6 | 2020 | 77098 | 0.030 |
Why?
|
Syndrome | 1 | 2021 | 3248 | 0.030 |
Why?
|
Sugar Phosphates | 1 | 2014 | 41 | 0.030 |
Why?
|
Emergencies | 1 | 2021 | 1164 | 0.030 |
Why?
|
Reference Values | 3 | 2011 | 4982 | 0.030 |
Why?
|
Angiography, Digital Subtraction | 1 | 2016 | 341 | 0.030 |
Why?
|
Punctures | 1 | 2016 | 372 | 0.030 |
Why?
|
Myocardial Infarction | 1 | 2015 | 11690 | 0.030 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 1996 | 236 | 0.030 |
Why?
|
Compartment Syndromes | 1 | 2016 | 153 | 0.030 |
Why?
|
Hypokalemia | 1 | 2015 | 153 | 0.030 |
Why?
|
Disaccharides | 1 | 2014 | 172 | 0.030 |
Why?
|
Ultrasonography, Doppler | 1 | 2016 | 458 | 0.030 |
Why?
|
Magnetic Resonance Angiography | 1 | 2020 | 1440 | 0.030 |
Why?
|
Italy | 1 | 2015 | 828 | 0.030 |
Why?
|
Prazosin | 1 | 1993 | 96 | 0.030 |
Why?
|
Rome | 1 | 2013 | 28 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 1 | 1999 | 1239 | 0.030 |
Why?
|
Limb Salvage | 1 | 2016 | 433 | 0.030 |
Why?
|
Glomerular Filtration Rate | 2 | 2011 | 2167 | 0.030 |
Why?
|
omega-N-Methylarginine | 2 | 2004 | 111 | 0.030 |
Why?
|
Psychophysiology | 1 | 1993 | 135 | 0.030 |
Why?
|
Warfarin | 1 | 2021 | 1493 | 0.030 |
Why?
|
Metformin | 1 | 2020 | 829 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2005 | 4379 | 0.030 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 1993 | 174 | 0.030 |
Why?
|
Survival Rate | 2 | 2018 | 12773 | 0.030 |
Why?
|
Hyperkalemia | 1 | 2015 | 218 | 0.030 |
Why?
|
Receptor, Endothelin A | 2 | 2002 | 58 | 0.030 |
Why?
|
Paracrine Communication | 1 | 2014 | 276 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2016 | 1583 | 0.030 |
Why?
|
Adolescent | 4 | 2023 | 85649 | 0.030 |
Why?
|
Constriction, Pathologic | 1 | 2016 | 1095 | 0.030 |
Why?
|
Inflammation Mediators | 2 | 2014 | 1889 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2005 | 4438 | 0.030 |
Why?
|
Lipids | 1 | 2003 | 3302 | 0.030 |
Why?
|
Inflammation | 2 | 2014 | 10578 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2020 | 2013 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1847 | 0.030 |
Why?
|
Oxidative Stress | 2 | 2012 | 3081 | 0.020 |
Why?
|
Pyrazoles | 1 | 2021 | 1970 | 0.020 |
Why?
|
Enalapril | 1 | 1993 | 327 | 0.020 |
Why?
|
Vaccination | 1 | 2023 | 3256 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 1788 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2023 | 2978 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39004 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2020 | 2658 | 0.020 |
Why?
|
Angiography | 1 | 2016 | 1636 | 0.020 |
Why?
|
Stress, Psychological | 3 | 1996 | 4229 | 0.020 |
Why?
|
Aspirin | 1 | 2002 | 3278 | 0.020 |
Why?
|
Amiodarone | 1 | 2011 | 212 | 0.020 |
Why?
|
Signal Transduction | 1 | 2013 | 23387 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 2935 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 1999 | 2043 | 0.020 |
Why?
|
Cardiovascular Agents | 1 | 2016 | 848 | 0.020 |
Why?
|
Ultrasonography | 1 | 2002 | 5978 | 0.020 |
Why?
|
Office Visits | 1 | 1993 | 598 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2002 | 12242 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2011 | 683 | 0.020 |
Why?
|
Radiography, Interventional | 1 | 2016 | 1095 | 0.020 |
Why?
|
Recovery of Function | 1 | 2019 | 2924 | 0.020 |
Why?
|
Paclitaxel | 1 | 2016 | 1707 | 0.020 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2012 | 608 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2018 | 3760 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2020 | 24913 | 0.020 |
Why?
|
Systole | 1 | 2011 | 956 | 0.020 |
Why?
|
Diastole | 1 | 2011 | 791 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2016 | 1573 | 0.020 |
Why?
|
Electric Countershock | 1 | 2011 | 535 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2013 | 764 | 0.020 |
Why?
|
Life Expectancy | 1 | 2015 | 1183 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8662 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2016 | 1483 | 0.020 |
Why?
|
Resistin | 1 | 2008 | 170 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2271 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3679 | 0.020 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2011 | 790 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8297 | 0.020 |
Why?
|
Coronary Angiography | 1 | 2018 | 4567 | 0.020 |
Why?
|
Renin-Angiotensin System | 1 | 2011 | 759 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2014 | 2211 | 0.020 |
Why?
|
Drug Resistance | 1 | 2012 | 1608 | 0.020 |
Why?
|
Exercise Tolerance | 1 | 2011 | 770 | 0.020 |
Why?
|
Elasticity | 1 | 2007 | 657 | 0.020 |
Why?
|
Phenotype | 1 | 2023 | 16331 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 12958 | 0.020 |
Why?
|
Glucose Clamp Technique | 1 | 2005 | 266 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2011 | 1520 | 0.020 |
Why?
|
Overweight | 1 | 2016 | 2366 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15056 | 0.020 |
Why?
|
Antioxidants | 1 | 2012 | 1659 | 0.020 |
Why?
|
Disease Progression | 1 | 2020 | 13256 | 0.010 |
Why?
|
Fatty Acids | 1 | 2012 | 1806 | 0.010 |
Why?
|
Heart Rate | 3 | 2002 | 4091 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9185 | 0.010 |
Why?
|
Myocytes, Cardiac | 1 | 2012 | 1636 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2022 | 7645 | 0.010 |
Why?
|
Critical Illness | 1 | 2016 | 2665 | 0.010 |
Why?
|
Phosphorylation | 1 | 2014 | 8436 | 0.010 |
Why?
|
Receptor, Endothelin B | 1 | 2002 | 41 | 0.010 |
Why?
|
Prospective Studies | 3 | 2011 | 53187 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2015 | 2536 | 0.010 |
Why?
|
Disease Management | 1 | 2013 | 2450 | 0.010 |
Why?
|
Adiponectin | 1 | 2008 | 1099 | 0.010 |
Why?
|
Vasomotor System | 1 | 2002 | 209 | 0.010 |
Why?
|
E-Selectin | 1 | 2004 | 579 | 0.010 |
Why?
|
Enzyme Inhibitors | 2 | 2004 | 3800 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18355 | 0.010 |
Why?
|
Interleukin-1beta | 1 | 2007 | 972 | 0.010 |
Why?
|
Placebos | 1 | 2005 | 1677 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8328 | 0.010 |
Why?
|
Immune System | 1 | 2005 | 804 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2012 | 18006 | 0.010 |
Why?
|
Blood Platelets | 1 | 2011 | 2506 | 0.010 |
Why?
|
Leptin | 1 | 2008 | 1593 | 0.010 |
Why?
|
Norepinephrine | 1 | 2002 | 909 | 0.010 |
Why?
|
Pedigree | 1 | 2007 | 4646 | 0.010 |
Why?
|
Vascular Resistance | 1 | 2002 | 936 | 0.010 |
Why?
|
Cytokines | 1 | 2014 | 7317 | 0.010 |
Why?
|
Research Design | 1 | 2015 | 5979 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10372 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2014 | 19223 | 0.010 |
Why?
|
Nitric Oxide Synthase | 1 | 2001 | 916 | 0.010 |
Why?
|
Survival Analysis | 1 | 2011 | 10248 | 0.010 |
Why?
|
Chronic Disease | 1 | 2011 | 9144 | 0.010 |
Why?
|
Child | 2 | 2018 | 77478 | 0.010 |
Why?
|
Single-Blind Method | 1 | 1999 | 1589 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2007 | 4414 | 0.010 |
Why?
|
Brain | 1 | 2021 | 26343 | 0.010 |
Why?
|
Young Adult | 1 | 2018 | 56350 | 0.010 |
Why?
|
Mice | 2 | 2012 | 81045 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2005 | 14554 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2002 | 10943 | 0.010 |
Why?
|
Echocardiography, Doppler | 1 | 1993 | 934 | 0.010 |
Why?
|
Rest | 1 | 1993 | 900 | 0.000 |
Why?
|
Cohort Studies | 1 | 2011 | 40450 | 0.000 |
Why?
|
Body Mass Index | 1 | 2003 | 12695 | 0.000 |
Why?
|
Algorithms | 1 | 2002 | 13853 | 0.000 |
Why?
|